Nicola Gökbuget

23.9k total citations · 5 hit papers
179 papers, 9.1k citations indexed

About

Nicola Gökbuget is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Oncology. According to data from OpenAlex, Nicola Gökbuget has authored 179 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 159 papers in Public Health, Environmental and Occupational Health, 116 papers in Hematology and 44 papers in Oncology. Recurrent topics in Nicola Gökbuget's work include Acute Lymphoblastic Leukemia research (158 papers), Chronic Myeloid Leukemia Treatments (93 papers) and Chronic Lymphocytic Leukemia Research (39 papers). Nicola Gökbuget is often cited by papers focused on Acute Lymphoblastic Leukemia research (158 papers), Chronic Myeloid Leukemia Treatments (93 papers) and Chronic Lymphocytic Leukemia Research (39 papers). Nicola Gökbuget collaborates with scholars based in Germany, United States and Italy. Nicola Gökbuget's co-authors include Dieter Hoelzer, Monika Brüggemann, D. Hoelzer, Matthias Stelljes, Stefan Schwartz, Max S. Topp, Heinz‐August Horst, Hagop M. Kantarjian, Giovanni Martinelli and Michael Kneba and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Nicola Gökbuget

166 papers receiving 8.9k citations

Hit Papers

Inotuzumab Ozogamicin versus Standard Therapy for Acute L... 2014 2026 2018 2022 2016 2018 2014 2017 2024 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
    2016 869 citations Daniel J. DeAngelo, Matthias Stelljes et al. profile →
  2. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia
    2018 516 citations Nicola Gökbuget, Hervé Dombret et al. Blood profile →
  3. Phase II Trial of the Anti-CD19 Bispecific T Cell–Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients With Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia
    2014 488 citations Max S. Topp, Nicola Gökbuget et al. Journal of Clinical Oncology profile →
  4. Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
    2017 298 citations Giovanni Martinelli, Nicolas Boissel et al. Journal of Clinical Oncology profile →
  5. Management of ALL in adults: 2024 ELN recommendations from a European expert panel
    2024 45 citations Nicola Gökbuget, Nicolas Boissel et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicola Gökbuget Germany 49 5.9k 4.7k 3.8k 1.8k 1.6k 179 9.1k
Anthony S. Stein United States 43 1.8k 0.3× 3.9k 0.8× 2.9k 0.8× 873 0.5× 523 0.3× 242 6.8k
Anthony V. Moorman United Kingdom 51 6.5k 1.1× 7.1k 1.5× 1.7k 0.5× 743 0.4× 2.4k 1.5× 183 10.2k
Miloslav Beran United States 46 2.3k 0.4× 5.2k 1.1× 1.8k 0.5× 1.7k 0.9× 502 0.3× 106 8.5k
Gerhard Zugmaier Germany 41 1.9k 0.3× 1.6k 0.4× 4.6k 1.2× 1.1k 0.6× 391 0.2× 146 7.4k
Norbert Claude Gorin France 45 1.5k 0.3× 4.4k 0.9× 1.9k 0.5× 991 0.6× 248 0.2× 188 6.9k
W M Crist United States 41 2.3k 0.4× 1.9k 0.4× 2.0k 0.5× 1.0k 0.6× 970 0.6× 75 6.1k
Georg Mann Austria 39 2.6k 0.4× 2.2k 0.5× 1.0k 0.3× 1.0k 0.6× 1.2k 0.7× 147 4.5k
Nicolas Boissel France 42 1.9k 0.3× 3.6k 0.8× 1.5k 0.4× 418 0.2× 466 0.3× 200 6.1k
Auayporn Nademanee United States 39 823 0.1× 3.1k 0.7× 3.3k 0.9× 3.2k 1.8× 455 0.3× 180 7.3k
David A. Rizzieri United States 44 990 0.2× 4.3k 0.9× 2.5k 0.7× 916 0.5× 233 0.1× 309 8.1k

Countries citing papers authored by Nicola Gökbuget

Since Specialization
Citations

This map shows the geographic impact of Nicola Gökbuget's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicola Gökbuget with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicola Gökbuget more than expected).

Fields of papers citing papers by Nicola Gökbuget

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicola Gökbuget. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicola Gökbuget. The network helps show where Nicola Gökbuget may publish in the future.

Co-authorship network of co-authors of Nicola Gökbuget

This figure shows the co-authorship network connecting the top 25 collaborators of Nicola Gökbuget. A scholar is included among the top collaborators of Nicola Gökbuget based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicola Gökbuget. Nicola Gökbuget is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wilke, Anne C. & Nicola Gökbuget. (2025). The role of blinatumomab in adult acute B lymphoblastic leukaemia. British Journal of Haematology. 207(1). 27–42.
2.
Gökbuget, Nicola, Nicolas Boissel, Sabina Chiaretti, et al.. (2024). Management of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 143(19). 1903–1930. 45 indexed citations breakdown →
3.
Neumann, Martín, Patrícia M. A. Silva, Jutta Ortiz-Tánchez, et al.. (2023). FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signaling. Scientific Reports. 13(1). 972–972. 5 indexed citations
4.
5.
Douer, Dan, Nicola Gökbuget, Wendy Stock, & Nicolas Boissel. (2021). Optimizing use of L-asparaginase–based treatment of adults with acute lymphoblastic leukemia. Blood Reviews. 53. 100908–100908. 19 indexed citations
6.
Lang, Fabian, Lydia Wunderle, Eberhard Schleyer, et al.. (2020). A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia. BMC Pharmacology and Toxicology. 21(1). 70–70. 28 indexed citations
7.
8.
Gökbuget, Nicola, Anjali S. Advani, Matthias Stelljes, et al.. (2019). Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research. 88. 106283–106283. 37 indexed citations
9.
Gökbuget, Nicola, Hervé Dombret, Massimiliano Bonifacio, et al.. (2018). Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 131(14). 1522–1531. 516 indexed citations breakdown →
10.
Gökbuget, Nicola, et al.. (2018). Die akute lymphatische Leukämie – Diagnostik, Subgruppen und Therapien. DMW - Deutsche Medizinische Wochenschrift. 143(18). 1311–1317. 2 indexed citations
11.
Nagel, Inga, Marius Bartels, Johannes Duell, et al.. (2017). Hematopoietic stem cell involvement in BCR-ABL1–positive ALL as a potential mechanism of resistance to blinatumomab therapy. Blood. 130(18). 2027–2031. 63 indexed citations
12.
Martinelli, Giovanni, Nicolas Boissel, Patrice Chevallier, et al.. (2017). Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study. Journal of Clinical Oncology. 35(16). 1795–1802. 298 indexed citations breakdown →
13.
Neumann, Martín, Sandra Heesch, Cornelia Schlee, et al.. (2013). Whole-exome sequencing in adult ETP-ALL reveals a high rate of DNMT3A mutations. Blood. 121(23). 4749–4752. 143 indexed citations
14.
Intermesoli, Tamara, Alessandro Rambaldi, Giuseppe Rossi, et al.. (2013). High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 98(11). 1718–1725. 34 indexed citations
15.
Heesch, Sandra, Martín Neumann, Stefan Schwartz, et al.. (2013). Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. Annals of Hematology. 92(6). 747–758. 46 indexed citations
16.
Gökbuget, Nicola & Dieter Hoelzer. (2006). Treatment of Adult Acute Lymphoblastic Leukemia. Hematology. 2006(1). 133–141. 98 indexed citations
17.
Rosen, O., H.-J. Müller, Nicola Gökbuget, et al.. (2003). Pegylated asparaginase in combination with high‐dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. British Journal of Haematology. 123(5). 836–841. 30 indexed citations
18.
Hoelzer, Dieter & Nicola Gökbuget. (2000). Recent approaches in acute lymphoblastic leukemia in adults. Critical Reviews in Oncology/Hematology. 36(1). 49–58. 103 indexed citations
19.
Gaßmann, W., Helmut Löffler, E. Thiel, et al.. (1997). Morphological and cytochemical findings in 150 cases of T‐lineage acute lymphoblastic leukaemia in adults. British Journal of Haematology. 97(2). 372–382. 21 indexed citations
20.
Rieder, Harald, Wolfgang Ludwig, W. Gaßmann, et al.. (1996). Prognostic significance of additional chromosome abnormalities in adult patients with Philadelphia chromosome positive acute lymphoblastic leukaemia. British Journal of Haematology. 95(4). 678–691. 62 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anthony S. Stein Breakdown of academic impact, for papers by Anthony V. Moorman Breakdown of academic impact, for papers by Miloslav Beran Breakdown of academic impact, for papers by Gerhard Zugmaier Breakdown of academic impact, for papers by Norbert Claude Gorin Breakdown of academic impact, for papers by W M Crist Breakdown of academic impact, for papers by Georg Mann Breakdown of academic impact, for papers by Nicolas Boissel Breakdown of academic impact, for papers by Auayporn Nademanee Breakdown of academic impact, for papers by David A. Rizzieri
Rankless by CCL
2026